MedTrace Logo

Bone MicroArchitecture Abatacept (BMA2)

NCT02675218 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2020-07-24

No results posted yet for this study

Summary

Rheumatoid Arthritis patients management reposes primarily on the use of disease-modifying antirheumatic drugs (DMARDs).

Among DMARDs available in 2015, researchers demonstrated the ability to reduce synovitis, biomarkers of inflammation, and bone destruction.

Given the demonstration of correlation between joint inflammation and structural progression at each joint level as well as the opportunity for bone remodeling with resolution of joint inflammation, researchers expect to observe an improvement in bone micro-architecture parameters specifically in rheumatoid arthritis patients without remaining joint inflammation 3 months following abatacept treatment initiation.

Conditions

  • Arthritis, Rheumatoid

Interventions

OTHER

Patients with rheumatoid arthritis

Doppler effect at 3 months after Abatacept treatment initiation.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Hubert MAROTTE, PhD · CHU SAINT-ETIENNE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-10
Primary Completion
2019-06-04
Completion
2019-06-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02675218 on ClinicalTrials.gov